CNS Therapeutics

Home >
Life Sciences >
Pharmaceutical >
Therapy >
CNS Therapeutics

Report price : $ 3 950
Publication date : June 2007
Length : 497 pages

CNS Therapeutics

This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$. The specific product segments analyzed are Anti-Alzheimer’s, Anti-Parkinson’s, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic pain), Anti-Psychotics, Anti-Depressants, and Others (includes Multiple Sclerosis, Insomnia, and ADHD). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region and product segment for the period of 2001 through 2010. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 132 companies including many key and niche players worldwide such as Abbott Laboratories, Akzo Nobel NV, Organon N.V, Alkermes, Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, CeNeS Pharmaceuticals PLC, Cephalon, Inc., Cognetix, Inc., Dainippon Sumitomo Pharma Co., Ltd., Elan Corporation PLC, Eli Lilly and Co, Fabre-Kramer Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Janssen Pharmaceutica NV, Janssen-Cilag, Merck & Co, Inc., Neurocrine Biosciences, Inc., Novartis AG., Sandoz International GmbH, Ortho-McNeil Neurologics, Inc., Otsuka Pharmaceutical Co., Ltd, Pfizer, Inc., Sanofi-Aventis, Schwarz Pharma AG, Sepracor, Inc., Shire PLC, Solvay Pharmaceuticals, Takeda Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd, UCB S.A., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.Executive Summary
1. Market Overview II-1
2. Trends and Issues II-4
3. Research & Development II-13
4. CNS Disorders - An Introduction II-20
5. Overview of Select CNS Drugs II-42
6. Product Innovations/Introductions II-48
7. Recent Industry Activity II-50
8. Focus on Select Players II-66
9. Global Market Perspective II-76

III.MARKET
1. The United States III-1
2. Canada III-27
3. Europe III-31
3a. France III-47
3b. Germany III-50
3c. Italy III-53
3d. The United Kingdom III-56
3e. Spain III-59
3f. Rest of Europe III-62
4. Asia-Pacific III-65
5. Latin America III-71
6. Rest of World III-73

IV.COMPETITION
1. Abbott Laboratories (USA) IV-1
2. Ablynx (Belgium) IV-11
3. Acadia Pharmaceuticals, Inc. (USA) IV-12
4. Acumen Pharmaceuticals, Inc. (USA) IV-13
5. Akzo Nobel NV (The Netherlands) IV-14
6. Alkermes, Inc. (USA) IV-26
7. Alpharx, Inc. (Canada) IV-30
8. Amarin Corporation PLC (UK) IV-32
9. Amorfix Life Sciences Ltd. (Canada) IV-33
10. Angiochem, Inc. (Canada) IV-34
11. Apotex, Inc. (Canada) IV-35
12. Astellas Pharma, Inc. (Japan) IV-36
13. AstraZeneca PLC (UK) IV-38
14. Avicena Group, Inc. (USA) IV-46
15. Avigen, Inc. (USA) IV-47
16. Bayer Schering Pharma AG (Germany) IV-49
17. Bentley & Remington (P)., Ltd. (India) IV-52
18. Biogen Idec, Inc. (USA) IV-54
19. Bionomics Ltd. (Australia) IV-59
20. Bionovo, Inc. (USA) IV-60
21. Biovail Corporation (Canada) IV-61
22. Boehringer Ingelheim GmbH (Germany) IV-63
23. Boston Life Sciences, Inc. (USA) IV-68
24. Brainstorm Cell Therapeutics, Inc. (USA) IV-69
25. Bristol-Myers Squibb Company (USA) IV-70
26. Britannia Pharmaceuticals Ltd. (UK) IV-77
27. CeNeS Pharmaceuticals PLC (UK) IV-78
28. Cephalon, Inc. (USA) IV-79
29. Ceregene, Inc. (USA) IV-82
30. Chakra Biotech Pte., Ltd. (Singapore) IV-83
31. China Aoxing Pharmaceutical Corporation (China) IV-83
32. Chlorion Pharma, Inc. (Canada) IV-84
33. Circadian Technologies Ltd. (Australia) IV-84
34. CLL Pharma (France) IV-85
35. Cognetix, Inc. (USA) IV-85
36. Cortex Pharmaceuticals, Inc. (USA) IV-86
37. Cyberkinetics Neurotechnology Systems, Inc. (USA) IV-87
38. Dainippon Sumitomo Pharma Company Limited (Japan) IV-89
39. Destin Pharma (Germany) IV-90
40. DOV Pharmaceutical, Inc. (USA) IV-91
41. D-Pharm Ltd. (Israel) IV-92
42. Drugfarm Laboratories (India) IV-93
43. Eisai Co., Ltd. (Japan) IV-95
44. Eisai, Inc. (USA) (A Subsidiary of Eisai Co., Ltd. (Japan)) IV-96
45. Elan Corporation PLC (Ireland) IV-98
46. Elekta AB (Sweden) IV-101
47. Eli Lilly And Company (USA) IV-103
48. Endo Pharmaceuticals, Inc. (USA) IV-107
49. EPIX Pharmaceuticals, Inc. (USA) IV-109
50. Ester Neurosciences Ltd. (Israel) IV-110
51. Evotec AG (Germany) IV-111
52. F. Hoffmann-La Roche Ltd. / Roche Holding Ltd. (Switzerland) IV-113
53. Fabre-Kramer Pharmaceuticals, Inc. (USA) IV-118
54. Forest Laboratories, Inc. (USA) IV-120
55. Galapagos NV (Belgium) IV-125
56. Gerolymatos, P. N., SA (Greece) IV-127
57. Glaxosmithkline PLC (UK) IV-128
58. H. Lundbeck AS (Denmark) IV-138
59. Icagen, Inc. (USA) IV-142
60. Immune Response Corporation, The (USA) IV-143
61. Impax Laboratories, Inc. (USA) IV-145
62. Johnson & Johnson (USA) IV-147
63. King Pharmaceuticals, Inc. (USA) IV-164
64. Kyowa Hakko Kogyo Co., Ltd. (Japan) IV-170
65. Lincoln Pharmaceutical Ltd. (India) IV-172
66. Lundbeck Espana SA (Spain) IV-172
67. MAP Pharmaceuticals, Inc. (USA) IV-173
68. Meda AB (Sweden) IV-175
69. Medtronic, Inc. (USA) IV-177
70. Memory Pharmaceuticals Corporation (USA) IV-180
71. Merck & Co., Inc. (USA) IV-182
72. Merz Pharmaceuticals GmbH (Germany) IV-189
73. Myriad Genetics, Inc. (USA) IV-190
74. Neuren Pharmaceuticals Ltd. (New Zealand) IV-192
75. Neurim Pharmaceuticals Ltd. (Israel) IV-193
76. Neurobiological Technologies, Inc. (USA) IV-194
77. Neurochem, Inc. (Canada) IV-195
78. Neurocrine Biosciences (USA) IV-196
79. Neurogen Corporation (USA) IV-197
80. Neurogesx, Inc. (USA) IV-198
81. Neurologix, Inc. (USA) IV-199
82. Neuromed Pharmaceuticals, Inc. (Canada) IV-200
83. NeuroSearch A/S (Denmark) IV-201
84. Newron Pharmaceuticals SpA (Italy) IV-202
85. Novartis AG (Switzerland) IV-203
86. NPS Pharmaceuticals (USA) IV-213
87. NsGene A/S (Denmark) IV-214
88. Nymox Pharmaceutical Corporation (Canada) IV-215
89. Orion Corporation (Finland) IV-216
90. Oryx Pharmaceuticals, Inc. (Canada) IV-217
91. Otsuka Pharmaceutical Co., Ltd. (Japan) IV-219
92. Paris Dakner Microspherules Pvt., Ltd. (India) IV-223
93. Pfizer, Inc. (USA) IV-224
94. Pharmacopeia, Inc. (USA) IV-230
95. PharmaSeed Bioservices (Israel) IV-231
96. Pharmidex Pharmaceutical Services Ltd. (UK) IV-232
97. Pharmos Corporation (USA) IV-233
98. Pozen, Inc. (USA) IV-234
99. Prestwick Pharmaceuticals, Inc. (USA) IV-235
100. Proneuron Biotechnologies (USA) IV-236
101. Proximagen Neuroscience PLC (UK) IV-237
102. Purdue Pharma LP (USA) IV-238
103. Ranbaxy Laboratories Ltd. (India) IV-240
104. Regen Therapeutics PLC (UK) IV-242
105. Repligen Corporation (USA) IV-243
106. Saila Impex (India) IV-244
107. Samaritan Pharmaceuticals, Inc. (USA) IV-246
108. Sanofi-Aventis (France) IV-248
109. Senexis Ltd. (UK) IV-254
110. Sepracor, Inc. (USA) IV-255
111. Shire Pharmaceuticals Group PLC / Shire PLC (UK) IV-258
112. Solvay Pharmaceuticals (France) IV-261
113. Somerset Pharmaceuticals, Inc. (USA) IV-261
114. Spectrum Pharmaceuticals, Inc. (USA) IV-262
115. StemCells, Inc. (USA) IV-263
116. Sygnis Pharma AG (Germany) IV-264
117. Takeda Pharmaceutical Company Limited (Japan) IV-265
118. Targacept, Inc. (USA) IV-271
119. Teva Pharmaceutical Industries Ltd. (Israel) IV-273
120. Titan Pharmaceuticals, Inc. (USA) IV-281
121. Torreypines Therapeutics, Inc. (USA) IV-282
122. Toyama Chemical Co., Ltd. (Japan) IV-283
123. Transition Therapeutics, Inc. (Canada) IV-284
124. UCB SA (Belgium) IV-285
125. Vernalis PLC (UK) IV-295
126. VistaGen Therapeutics, Inc. (USA) IV-296
127. Voyager Pharmaceutical Corporation (USA) IV-297
128. Wyeth (USA) IV-298
129. Xenoport, Inc. (USA) IV-307
130. Zentiva, AS Praha (Czech Republic) IV-308
131. Zogenix, Inc. (USA) IV-309
132. Zydus Cadila Healthcare Ltd. (India) IV-310

RELATED REPORTS

Disease and Therapy Review: Alzheimer's Disease

$ 900
January 2007
8 pages

The Alzheimer's Dementia Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments. Dosing information and treatment costs are provided for Aricept, Namenda, Razadyne, and Exelon. Genera ...

Industries : Therapy | Countries : Canada, China, Japan, India, France, Italy, United Kingdom

Disease and Therapy Review: Major Depressive Disorder

$ 900
January 2007
12 pages

The Major Depressive Disorder Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments, including SSRIs and atypical antidepressants, tricyclic antidepressants, monoamine oxidase inhibi ...

Industries : Therapy | Countries : Mexico, Canada, USA, China, Japan, Germany, Spain, France, United Kingdom

Disease and Therapy Review: Schizophrenia

$ 900
January 2007
8 pages

The Schizophrenia Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments. Dosing information and treatment costs are provided for a wide range of products. General information is incl ...

Industries : Therapy | Countries : Canada, China, Japan, India, Germany, Italy, United Kingdom

Disease and Therapy Review: Bipolar Disorder

$ 900
January 2007
8 pages

The Bipolar Disorder Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments including mood stabilizers, antidepressants, antipsychotics, and anticonvulsants. Dosing information and co ...

Industries : Therapy | Countries : Mexico, Canada, Germany, Italy, United Kingdom

Disease and Therapy Review: Senile Dementia

$ 900
January 2007
11 pages

The Senile Dementia Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis and dementia types, and an overview of treatments. Dosing information and treatment costs are provided for Aricept, Namenda, Razadyne, and ...

Industries : Therapy | Countries : Canada, China, Japan, India, Germany, Spain, France, Italy, United Kingdom

Alzheimer’s and Parkinson’s Disease

$ 3 950
July 2007
531 pages

This report analyzes the worldwide markets for Alzheimer’s and Parkinson’s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, & O ...

Industries : Therapy | Countries : Canada, USA, Japan, Germany, Spain, France, Italy, United Kingdom

CNS Therapeutics - get our PDF brochure

24/7 Customer Service

Contact Shadi now !

(866) 682 9815
Ask Shadi by email

Related industries

Therapy Industry
- in Canada
- in USA
- in China
- in Japan
- in Germany

Related countries

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.